{"id":"NCT01566604","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease","officialTitle":"A 26-week Treatment, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 (50 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2012-03-29","resultsPosted":"2014-08-08","lastUpdate":"2014-08-08"},"enrollment":460,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"NVA237","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NVA237","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess of the efficacy and safety of a once-daily, 50µg inhalation of NVA237 in moderate to severe chronic obstructive pulmonary disease (COPD) patients over 26 weeks treatment.","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in One Second (FEV1)","timeFrame":"12 weeks","effectByArm":[{"arm":"NVA237","deltaMin":1.204,"sd":0.0135},{"arm":"Placebo","deltaMin":1.063,"sd":0.016}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":32,"countries":["China","India","Philippines","South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":305},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection"]}}